Start Submission Become a Reviewer

Reading: Foetal valporate syndrome; the risk is still out there: a case report

Download

A- A+
Alt. Display

Case Reports

Foetal valporate syndrome; the risk is still out there: a case report

Authors:

J. C. Ranasinghe ,

Lady Ridgeway Hospital For Children, Colombo, LK
X close

M. M. Manamperi,

Lady Ridgeway Hospital For Children, Colombo, LK
X close

R. C. Ediriweera

Lady Ridgeway Hospital For Children, Colombo, LK
X close

Abstract

Sodium valproate should be used cautiously in women belonging to the child-bearing age due to the potential teratogenicity of the drug. It has been found that mothers who had taken sodium valproate during pregnancy have delivered babies with foetal valproate syndrome, evident by the features such as intrauterine growth retardation (IUGR), suggestive facial features, microcephaly, cardiac and eye anomalies, learning disabilities and developmental delay. We report a patient with late diagnosis of foetal valproate syndrome whose mother had taken 1000 mg/ day of sodium valproate throughout the pregnancy. In addition to the characteristic facial features, she had bilateral corneal clouding, small joint contractures with early clawing and partial anomalous pulmonary venous drainage (PAPVD). This cardiac anomaly has not been well described in literature. This case highlights the importance of active surveillance of teratogenic side effects early in the life.

How to Cite: Ranasinghe, J.C., Manamperi, M.M. and Ediriweera, R.C., 2021. Foetal valporate syndrome; the risk is still out there: a case report. Anuradhapura Medical Journal, 15(2), pp.31–34. DOI: http://doi.org/10.4038/amj.v15i2.7700
Published on 30 Dec 2021.
Peer Reviewed

Downloads

  • PDF (EN)

    comments powered by Disqus